Innovent Biologics Licenses IBI355 to Spero Therapeutics in Deal Worth Up to $1.1B
2026-07-15 08:40:13
Innovent Biologics (1801) has entered into an exclusive license agreement with Spero Therapeutics (SPRO) for IBI355, a third-generation Fc-silent anti-CD40L antibody, according to Ming Pao. Under the terms, Spero will obtain exclusive global rights outside Greater China (mainland China, Hong Kong, Macau, and Taiwan) to develop, research, manufacture, and commercialize SP001 (IBI355). Innovent will receive an upfront payment, development, regulatory, and sales-based milestone payments totaling approximately $1.1 billion, as well as tiered royalties on future net sales of the product.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
美国比特币ETF单日净流入1.81亿美元
